20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Hemab Therapeutics Holdings, Inc. Common Stock (COAG) operates in the BIOTECHNOLOGY industry and is headquartered in Cambridge, United States with about 59 employees. Its market capitalization is roughly $2 billion. In the fiscal year ended 2025-12-31, COAG reported $0M in revenue and ($64M) in net income.
Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark.
Interactive charts & full statements →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 |
|---|---|---|---|
| Total Revenue | — | $0M | $0M |
| Operating Income (EBIT) | ($50M) | ($70M) | ($50M) |
| Operating Margin % | — | — | — |
| Net Income | ($47M) | ($64M) | ($49M) |
| Net Margin % | — | — | — |
| EBITDA | ($50M) | ($70M) | — |
| Earnings Per Share (EPS) | $-1.32 | $-2.33 | $-1.10 |
| Shares Outstanding (M) | 30M | 27M | 44M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-03-31 |
|---|---|---|---|
| Total Revenue | — | $0M | $0M |
| Operating Income (EBIT) | ($26M) | ($24M) | ($17M) |
| Operating Margin % | — | — | — |
| Net Income | ($24M) | ($23M) | ($15M) |
| Net Margin % | — | — | — |
| EBITDA | ($26M) | ($24M) | — |
| Earnings Per Share (EPS) | $-0.80 | $-0.51 | — |
| Shares Outstanding (M) | 30M | 44M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 |
|---|---|---|---|
| Cash from Operations (CFO) | ($44M) | ($61M) | ($46M) |
| Capital Expenditures (CapEx) | $0M | $0M | $0M |
| Free Cash Flow (FCF) | ($44M) | ($61M) | ($46M) |
| FCF Margin % | — | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-03-31 |
|---|---|---|---|
| Cash from Operations (CFO) | ($23M) | ($22M) | ($13M) |
| Capital Expenditures (CapEx) | $0M | $0M | $0M |
| Free Cash Flow (FCF) | ($23M) | ($22M) | ($13M) |
| FCF Margin % | — | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 |
|---|---|---|---|
| Total Assets | $468M | $195M | $96M |
| Cash & Cash Equivalents | $237M | $88M | $74M |
| Total Liabilities | $14M | $371M | $212M |
| Total Debt (Short + Long-Term) | $0M | $1M | $0M |
| Total Shareholders' Equity | $454M | ($177M) | ($115M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive COAG viewer.
About TickerBase · Data methodology & sources · Privacy · Terms